EE200300103A - Kontratseptsioonimeetod ja kontratseptiivi manustatav vorm - Google Patents

Kontratseptsioonimeetod ja kontratseptiivi manustatav vorm

Info

Publication number
EE200300103A
EE200300103A EEP200300103A EEP200300103A EE200300103A EE 200300103 A EE200300103 A EE 200300103A EE P200300103 A EEP200300103 A EE P200300103A EE P200300103 A EEP200300103 A EE P200300103A EE 200300103 A EE200300103 A EE 200300103A
Authority
EE
Estonia
Prior art keywords
contraception
administered
Prior art date
Application number
EEP200300103A
Other languages
English (en)
Estonian (et)
Inventor
Kulmann Hermann
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200300103A publication Critical patent/EE200300103A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EEP200300103A 2000-09-14 2001-09-05 Kontratseptsioonimeetod ja kontratseptiivi manustatav vorm EE200300103A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045380A DE10045380A1 (de) 2000-09-14 2000-09-14 Verfahren zur Kontrazeption und dessen Darreichungsform
PCT/EP2001/010207 WO2002022110A2 (en) 2000-09-14 2001-09-05 Contraception process and administration form for the same

Publications (1)

Publication Number Publication Date
EE200300103A true EE200300103A (et) 2005-02-15

Family

ID=7656125

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300103A EE200300103A (et) 2000-09-14 2001-09-05 Kontratseptsioonimeetod ja kontratseptiivi manustatav vorm

Country Status (32)

Country Link
US (2) US8076317B2 (me)
EP (2) EP2153849A3 (me)
JP (3) JP2004508398A (me)
KR (3) KR20030031185A (me)
CN (1) CN100560132C (me)
AR (1) AR030737A1 (me)
AT (1) ATE447972T1 (me)
AU (2) AU8405201A (me)
BG (2) BG107625A (me)
BR (1) BR0113902A (me)
CA (1) CA2420292C (me)
CZ (1) CZ2003723A3 (me)
DE (2) DE10045380A1 (me)
EA (1) EA006875B1 (me)
EE (1) EE200300103A (me)
HK (1) HK1060305A1 (me)
HR (1) HRP20030294A2 (me)
HU (1) HUP0301042A3 (me)
IL (2) IL154521A0 (me)
ME (1) ME00291B (me)
MX (1) MXPA03002070A (me)
NO (1) NO20031152L (me)
NZ (1) NZ524448A (me)
PE (1) PE20020425A1 (me)
PL (1) PL361161A1 (me)
SK (1) SK3102003A3 (me)
TW (1) TWI297271B (me)
UA (1) UA93650C2 (me)
UY (1) UY26932A1 (me)
WO (1) WO2002022110A2 (me)
YU (1) YU19003A (me)
ZA (1) ZA200301359B (me)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
AU2011226911B2 (en) * 2004-04-30 2014-06-19 Bayer Intellectual Property Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
EP1655031A1 (de) 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
TW200727920A (en) * 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
TW200744610A (en) * 2005-06-21 2007-12-16 Organon Nv New regimens for controlled drug delivery devices for contraception
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
GB0623813D0 (en) * 2006-11-29 2007-01-10 Stephenson Group Ltd Foam reduction
DE102007011486A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2365103C3 (de) * 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0792152B1 (en) * 1994-11-22 2004-04-14 Balance Pharmaceuticals, Inc. Methods of contraception
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
JP2000515890A (ja) 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション プロゲスチンとエストロゲンとの混合剤からなる一相性避妊法およびキット
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy

Also Published As

Publication number Publication date
HRP20030294A2 (en) 2005-02-28
PE20020425A1 (es) 2002-06-15
AU2001284052B2 (en) 2006-11-30
NZ524448A (en) 2005-03-24
UY26932A1 (es) 2001-12-28
US20120129823A1 (en) 2012-05-24
EP2153849A2 (en) 2010-02-17
BG107625A (bg) 2003-11-28
EP1317286B1 (en) 2009-11-11
AU8405201A (en) 2002-03-26
US20040219174A1 (en) 2004-11-04
BR0113902A (pt) 2003-07-22
EP1317286A2 (en) 2003-06-11
HUP0301042A2 (hu) 2003-10-28
KR20090033502A (ko) 2009-04-03
MEP37608A (en) 2011-02-10
TWI297271B (en) 2008-06-01
KR20030031185A (ko) 2003-04-18
DE10045380A1 (de) 2002-04-04
BG111090A (bg) 2012-03-30
HUP0301042A3 (en) 2010-03-29
JP2013241456A (ja) 2013-12-05
ZA200301359B (en) 2004-02-05
SK3102003A3 (en) 2003-09-11
CA2420292C (en) 2010-12-14
UA93650C2 (ru) 2011-03-10
EA006875B1 (ru) 2006-04-28
US8536156B2 (en) 2013-09-17
CA2420292A1 (en) 2002-03-21
AR030737A1 (es) 2003-09-03
NO20031152D0 (no) 2003-03-13
CZ2003723A3 (cs) 2003-06-18
KR101240232B1 (ko) 2013-03-07
PL361161A1 (en) 2004-09-20
KR20100056577A (ko) 2010-05-27
ATE447972T1 (de) 2009-11-15
ME00291B (me) 2011-05-10
CN100560132C (zh) 2009-11-18
JP2004508398A (ja) 2004-03-18
DE60140462D1 (de) 2009-12-24
EP2153849A3 (en) 2011-09-14
IL154521A (en) 2014-05-28
JP2013006866A (ja) 2013-01-10
US8076317B2 (en) 2011-12-13
YU19003A (sh) 2006-05-25
CN1455681A (zh) 2003-11-12
WO2002022110A2 (en) 2002-03-21
MXPA03002070A (es) 2003-06-24
WO2002022110A3 (en) 2002-07-04
IL154521A0 (en) 2003-09-17
HK1060305A1 (en) 2004-08-06
EA200300338A1 (ru) 2003-08-28
NO20031152L (no) 2003-05-14

Similar Documents

Publication Publication Date Title
EE200300103A (et) Kontratseptsioonimeetod ja kontratseptiivi manustatav vorm
AR028027A1 (es) Componente de compuestos en secciones y procedimiento para producir el mismo
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
CY2013011I1 (el) Μεθοδος χορηγησης διφωσφονικων
EE200300151A (et) Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks
PL401469A1 (pl) Pochodna azabicykliczna, sposób jej wytwarzania, jej zastosowanie w medycynie oraz zawierajaca pochodna kompozycja
EE200200328A (et) Multši kompositsioon ja meetod
NO20030844L (no) Fremgangsmåte for fremstilling av N-aryl-antranilinsyrer og derivater derav
EE05062B1 (et) Dihdroksestrite ja nende derivaatide valmistamismeetod
LTPA2014005I1 (lt) Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
EE200200666A (et) Meetod tsüklopropüülkarboksüülhappe estrite ja derivaatide valmistamiseks
EE05387B1 (et) KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine
AR026046A1 (es) NUEVA COMPOSICIoN Y MÉTODO PARA ESTABILIZAR LA MISMA
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
EE05020B1 (et) Glburiidi ravimkoostis
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
CY2009001I2 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
EE200200607A (et) 2-atsüülindoolderivaadid ja nende kasutamine kasvajavastaste ravimitena
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
EE200200271A (et) Ravimkombinatsioonid ning nende kasutamine
AR028289A1 (es) Metodo para modificar la composicion de lignina y aumentar la digestibilidad in vivo de forrages
EE200200105A (et) Radiofarmatseutilised saadused ja nende valmistamise meetod
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
EP1326625A4 (en) IMMUNOGENIC COMPOSITION OF HEPATITIS C AND METHODS OF USING THE SAME
GB0312566D0 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin